Bright Minds Biosciences
Update in progressDRUG (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Bright Minds Biosciences is a New York–based biotechnology company developing therapeutics for severe neurological and neuropsychiatric diseases. Its portfolio centers on 5-HT2 receptor programs and BMB-101, which has completed a Phase 1 trial and is in Phase 2 for developmental and epileptic encephalopathies and absence seizures. It also develops BMB-201, BMB-202, and BMB-105, a 5-HT2C agonist for Prader-Willi syndrome. The company collaborates with Firefly Neuroscience to analyze EEG data in its BREAKTHROUGH study. Founded 2017.
Company score
- Sentiment
- 0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.22
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Ian McDonald
- Founded2017
- Employees26
- Websitebrightmindsbio.com
Identifiers
- ISINCA10919W1086
- FIGIBBG00ZKX9FP7
- CUSIP10919W108
- CIK0001827401